Table 3.
Adjusted relative risk (RR) of starting statin treatment among participants in population-based studies 2000–2002, who reported never use of statins at baseline
| Non-CVD/diabetes group (n #x003D; 18 547†) | CVD/diabetes group (n = 609†) | Total (n = 19 156†) | ||||
|---|---|---|---|---|---|---|
| Covariate | RR‡ | 95% CI | RR‡ | 95% CI | RR‡ | 95% CI |
| Education*: | ||||||
| Low | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |
| Middle | 1.00 | 0.89, 1.12 | 0.94 | 0.73, 1.21 | 0.99 | 0.89, 1.11 |
| High | 0.91 | 0.79, 1.05 | 1.35 | 1.00, 1.81 | 0.95 | 0.83, 1.08 |
| Women vs. men | 0.85 | 0.77, 0.93 | 0.82 | 0.66, 1.04 | 0.84 | 0.77, 0.93 |
| Age 59–61 vs. 40–46 | 1.91 | 1.72, 2.14 | 1.39 | 1.06, 1.82 | 1.88 | 1.69, 2.08 |
| CVD/diabetes vs. non-CVD/diabetes | – | – | – | – | 2.81 | 2.45, 3.22 |
| Serum total cholesterol per mmol l−1 | 1.98 | 1.91, 2.06 | 1.36 | 1.22, 1.51 | 1.93 | 1.86, 2.00 |
| HDL-cholesterol per mmol l−1 | 0.47 | 0.40, 0.54 | 0.43 | 0.30, 0.62 | 0.46 | 0.40, 0.53 |
| Systolic blood pressure per 10 mmHg | 1.13 | 1.10, 1.15 | 1.05 | 0.99, 1.12 | 1.12 | 1.10, 1.15 |
| Medication for hypertension at baseline vs. no medication | 1.63 | 1.42, 1.88 | 1.33 | 1.06, 1.67 | 1.56 | 1.38, 1.76 |
| BMI per 5 kg m−2 | 1.05 | 0.99, 1.11 | 0.97 | 0.86, 1.10 | 1.04 | 0.98, 1.10 |
| Family history yes vs. no | 1.43 | 1.30, 1.56 | 1.28 | 1.03, 1.59 | 1.41 | 1.29, 1.53 |
| Smoking yes vs. no | 1.21 | 1.10, 1.34 | 1.14 | 0.90, 1.44 | 1.21 | 1.10, 1.32 |
| Physical active vs. inactive | 0.95 | 0.85, 1.05 | 1.09 | 0.87, 1.37 | 0.96 | 0.87, 1.06 |
| Married yes vs. no | 1.07 | 0.97, 1.19 | 1.32 | 1.05, 1.68 | 1.10 | 1.01, 1.21 |
Separate models for two subgroups and the total.
*
Education: low, no, primary or lower secondary; middle, higher secondary or high school; high, college/university.
†
Only participants with complete data.
‡
Adjusted for all covariates in the model and county of residence. CVD, cardiovascular disease; HDL, high-density lipoprotein; BMI, body mass index.